InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the clinical trial of novel CDH17 targeted ADC, ICP-B208, in China.

CDH17 is a calcium-dependent cell adhesion protein that plays a key role in tumor cell proliferation, migration, and metastasis. Its tumor-restricted expression and functional role in cancer biology make CDH17 an attractive and differentiated target for the ADC therapy, which can be developed for the treatment of gastrointestinal cancers, including colorectal, gastric, pancreatic ductal adenocarcinoma, and biliary tract cancer. Currently, there are no approved CDH17 targeted ADCs globally.

Dr. Jasmine Cui, Co-Founder, Chairwoman, and CEO of InnoCare, said, “I am pleased to see the clinical development progress of our second ADC drug, following ICP-B794, our novel ADC targeting B7-H3. Through our innovated platform, we have developed multiple ADC candidates with strong tumor killing effects and an excellent safety profile, which will offer better treatment options for cancer patients globally.”